ELYM Profile
Eliem Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative therapies for disorders related to neuronal excitability. The company's focus includes addressing significant unmet medical needs in areas such as chronic pain, neuropsychiatry, epilepsy, and various conditions affecting both the peripheral and central nervous systems. Eliem's pipeline is centered on advancing treatments that aim to improve patient outcomes in these complex fields.
The company's lead drug candidates include ETX-810 and ETX-155. ETX-810 is being investigated in a Phase IIa clinical trial for its potential to treat chronic pain. Meanwhile, ETX-155 is in Phase I clinical trials for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. These clinical trials represent Eliem's commitment to addressing challenging neurological and psychiatric conditions through targeted therapeutic interventions.
In addition to its lead candidates, Eliem Therapeutics is advancing several preclinical programs. These include the Kv7 Program, which targets conditions such as pain, epilepsy, and depression, and the Anxiolytic program, focused on developing treatments for generalized anxiety disorder. These preclinical efforts demonstrate the company’s dedication to expanding its therapeutic portfolio and exploring new avenues for treating neuropsychiatric and neurological disorders.
Incorporated in 2018 and headquartered in Redmond, Washington, Eliem Therapeutics has rapidly established itself as a key player in the biotechnology sector. The company's innovative approach and robust pipeline reflect its mission to advance treatment options for patients with complex and underserved neurological and psychiatric conditions.
|
